0:00
0:00
U.S. Clinical Trial Investigates Medication to Prolong Dogs' Lifespan
Loyal, a company based in San Francisco, is undertaking a large-scale study to evaluate the impacts of a possible longevity medication for older dogs.
A clinical trial is currently being conducted in the United States to assess a medication that could potentially increase the lifespan of dogs.
This research, called the STAY trial, is led by Loyal, an animal health firm based in San Francisco.
The double-blind, placebo-controlled study includes at least one thousand senior dogs, with the company aiming to secure approval from the U.S. Food and Drug Administration (FDA) based on the results.
The trial is a continuation of positive preclinical and pilot studies.
According to Alex Robb, medical director at Goodheart Animal Health Center in Colorado, the dogs involved will receive daily doses of the drug over a four-year period, alongside regular clinical evaluations.
Researchers will assess whether the medication has a significant effect on lifespan once the trial concludes.
To be eligible for the study, dogs must be a minimum of ten years old and weigh at least fourteen pounds.
Owners are required to transfer their pet's primary care to a participating clinic and commit to multiple veterinary visits throughout the four-year period.
The first year includes six visits, followed by two visits each year thereafter.
The study aims to explore the factors related to canine aging, particularly their higher metabolic rate when compared to humans.
While veterinary advancements have enhanced healthcare for dogs, their average lifespan has not kept pace with the increasing lifespan of humans.
Loyal plans to utilize the data gathered to seek conditional FDA approval for the drug by the year's end.
Recruitment for the trial is currently ongoing at various clinics nationwide.
This research, called the STAY trial, is led by Loyal, an animal health firm based in San Francisco.
The double-blind, placebo-controlled study includes at least one thousand senior dogs, with the company aiming to secure approval from the U.S. Food and Drug Administration (FDA) based on the results.
The trial is a continuation of positive preclinical and pilot studies.
According to Alex Robb, medical director at Goodheart Animal Health Center in Colorado, the dogs involved will receive daily doses of the drug over a four-year period, alongside regular clinical evaluations.
Researchers will assess whether the medication has a significant effect on lifespan once the trial concludes.
To be eligible for the study, dogs must be a minimum of ten years old and weigh at least fourteen pounds.
Owners are required to transfer their pet's primary care to a participating clinic and commit to multiple veterinary visits throughout the four-year period.
The first year includes six visits, followed by two visits each year thereafter.
The study aims to explore the factors related to canine aging, particularly their higher metabolic rate when compared to humans.
While veterinary advancements have enhanced healthcare for dogs, their average lifespan has not kept pace with the increasing lifespan of humans.
Loyal plans to utilize the data gathered to seek conditional FDA approval for the drug by the year's end.
Recruitment for the trial is currently ongoing at various clinics nationwide.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
